ASX Announcement **18 November 2026**

GSS not proceeding with Proposed Merger with Microba Life Sciences

- Genetic Signatures Limited (ASX: GSS) (**GSS**) has resolved not to proceed with the Proposed Merger with Microba Life Sciences Limited (ASX: MAP) (**Microba**) in light of Microba's announcement that it will not have financial capacity to complete the Proposed Merger without additional capital.

Genetic Signatures Limited (ASX: GSS) (**GSS** or the **Company**) refers to its announcement of 21 October 2026 which disclosed an update to the commercial terms of the proposed merger of GSS and Microba Life Sciences Limited (ASX: MAP) (**Microba**) (**Proposed Merger**), as well as Microba's request for a voluntary suspension of trading in its shares dated 17 November 2026.

After many months of discussions, engagement and due diligence, GSS notifies the market that it is no longer pursuing the Proposed Merger with Microba. Both GSS and Microba have invested a lot of time and effort into pursuing the Proposed Merger. However, in light of Microba's notification to the market that it does not have the financial capacity to complete the Proposed Merger without additional capital, GSS has resolved not to proceed with the Proposed Merger.

GSS notes that it had been in discussions with Microba regarding the possibility of providing unsecured debt funding to assist Microba with its working capital requirements during the implementation of the Proposed Merger. Ultimately, however, the GSS Board determined that it was not prepared to proceed with such an arrangement, having regard to the risks associated and the potential regulatory requirements.

GSS will issue a separate announcement shortly formally withdrawing Resolution 4 from the Agenda of GSS's upcoming annual general meeting to be held on 30 November 2026.

GSS will also provide a further market announcement with respect to the impact of this announcement and the withdrawal of Resolution 4 on the Takeovers Panel Application that was made by BCAL Diagnostics Limited on 13 November 2026.

This announcement has been authorised for release by the Board of Directors of Genetic Signatures Limited.

– END –

For further information contact:

Mike Aicher
Chair
Genetic Signatures
info@geneticsignatures.com

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

About Microba Life Sciences

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba – Expect better. www.microba.com

Genetic Signatures Ltd ABN 30 095 913 205
7 Eliza Street, Newtown NSW 2042
Telephone + 61 (2) 9870 7580

Forward-looking statements

This announcement may contain certain 'forward-looking statements' about the financial condition, results of operations and business of GSS, and certain plans and objectives of the Board and management of GSS, including in relation to the Proposed Merger. Forward-looking statements can generally be identified by words such as 'may', 'could', 'believes', 'plan', 'will', 'likely', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These risks and uncertainties may include, but are not limited to, the outcome and effects of the subject matter of this announcement, including whether the Proposed Merger will be implemented on the revised terms or at all, its timing, the number of GSS securities to be issued, the ownership structure of GSS on implementation, and the timing and content of the Further Addendum. You are cautioned not to place undue reliance on forward-looking statements, as actual outcomes may differ materially from them.

Any forward-looking statements, opinions and estimates provided in this announcement necessarily involve uncertainties, assumptions, contingencies and other factors, and unknown risks may arise, many of which are outside the control of GSS and Microba. The actual results, achievement or performance of GSS, Microba, or of the combined group, may be materially different from any future results, achievement or performance expressed or implied by such forward-looking statements. Forward-looking statements, including without limitation guidance on future plans, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Such forward-looking statements speak only as of the date of this announcement. To the maximum extent permitted by law, each of GSS and Microba disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise.

Genetic Signatures Ltd ABN 30 095 913 205
7 Eliza Street, Newtown NSW 2042
Telephone + 61 (2) 9870 7580